^
Association details:
| Biomarker: | IGH mutation + Chr del(13q) |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Regimen: | FCR (cyclophosphamide + fludarabine IV + Rituxan (rituximab)) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
001 | TOWARDS CONTROL OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH TARGETED AGENTS
Published date:
06/09/2021
Excerpt:
...FCR treatment of CLL patients with the combined occurrence of mutated IGHV genes plus del(13q), del(11q) or trisomy 12 yielded an overall survival rate above 90% at 5 years...
